CTSB and cutaneous melanoma: But CEP has been poorly studied in cutaneous melanoma, and in our study, it not only downregulates cathepsin B levels but also possesses novel antitumor mechanisms and inhibits primary cutaneous melanoma activity and metastasis by either topical application or intra-tumoral injection in mice.